The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: GSK plc 2024" company profile has been added to ResearchAndMarkets.com's offering. GSK plc (GSK) is a healthcare ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...

The Department of Homeland Security is asking for the Internal Revenue Service to help crack down on immigration, according ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

The theme of International Women's Day was "inspiring change" and GSK's take on that was to profile inspiring change in the workplace, with content published on the company's website shared via a ...

“That profile ... of GSK’s plans for obesity—that is to say, Wood still doesn’t intend on moving directly into the heavily populated landscape, but that doesn’t mean the company isn ...

The safety and tolerability analysis from RUBY Part 1 showed a safety profile for Jemperli ... Recently, GSK agreed to acquire IDRx, Inc., a biopharmaceutical company focused on precision ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...